These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 29324832

  • 1. Differential microRNA expression in breast cancer with different onset age.
    Tsai HP, Huang SF, Li CF, Chien HT, Chen SC.
    PLoS One; 2018; 13(1):e0191195. PubMed ID: 29324832
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
    Terkelsen T, Russo F, Gromov P, Haakensen VD, Brunak S, Gromova I, Krogh A, Papaleo E.
    Breast Cancer Res; 2020 Jun 30; 22(1):73. PubMed ID: 32605588
    [Abstract] [Full Text] [Related]

  • 4. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.
    Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K.
    PLoS One; 2013 Jun 30; 8(2):e55910. PubMed ID: 23405235
    [Abstract] [Full Text] [Related]

  • 5. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ.
    Breast Cancer Res; 2009 Jun 30; 11(3):R27. PubMed ID: 19432961
    [Abstract] [Full Text] [Related]

  • 6. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.
    Zhang X, He Q, Sun L, Zhang Y, Qin S, Fan J, Wang J.
    Dis Markers; 2019 Jun 30; 2019():6057280. PubMed ID: 31929841
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
    Moi L, Braaten T, Al-Shibli K, Lund E, Busund LR.
    J Transl Med; 2019 Oct 03; 17(1):334. PubMed ID: 31581940
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
    Wang B, Li J, Sun M, Sun L, Zhang X.
    IUBMB Life; 2014 May 03; 66(5):371-7. PubMed ID: 24846313
    [Abstract] [Full Text] [Related]

  • 12. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
    Chang YY, Kuo WH, Hung JH, Lee CY, Lee YH, Chang YC, Lin WC, Shen CY, Huang CS, Hsieh FJ, Lai LC, Tsai MH, Chang KJ, Chuang EY.
    Mol Cancer; 2015 Feb 10; 14():36. PubMed ID: 25888956
    [Abstract] [Full Text] [Related]

  • 13. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.
    Chen X, Wang YW, Zhu WJ, Li Y, Liu L, Yin G, Gao P.
    Hum Pathol; 2018 Jun 10; 76():122-132. PubMed ID: 29555574
    [Abstract] [Full Text] [Related]

  • 14. MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?
    Cizeron-Clairac G, Lallemand F, Vacher S, Lidereau R, Bieche I, Callens C.
    BMC Cancer; 2015 Jul 05; 15():499. PubMed ID: 26141719
    [Abstract] [Full Text] [Related]

  • 15. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.
    Koleckova M, Ehrmann J, Bouchal J, Janikova M, Brisudova A, Srovnal J, Staffova K, Svoboda M, Slaby O, Radova L, Vomackova K, Melichar B, Veverkova L, Kolar Z.
    Sci Rep; 2021 Mar 04; 11(1):5145. PubMed ID: 33664322
    [Abstract] [Full Text] [Related]

  • 16. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C, Tan W, Chen K, You N, Zhu S, Liang G, Xie X, Li Q, Zeng Y, Ouyang N, Li Z, Zeng M, Zhuang S, Lau WY, Liu Q, Yin D, Wang X, Su F, Song E.
    EBioMedicine; 2016 Sep 04; 11():199-209. PubMed ID: 27566954
    [Abstract] [Full Text] [Related]

  • 17. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
    Xing AY, Wang B, Li YH, Chen X, Wang YW, Liu HT, Gao P.
    Pathol Oncol Res; 2021 Sep 04; 27():1609753. PubMed ID: 34257614
    [Abstract] [Full Text] [Related]

  • 18. MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer.
    Hamurcu Z, Sener EF, Taheri S, Nalbantoglu U, Kokcu ND, Tahtasakal R, Cınar V, Guler A, Ozkul Y, Dönmez-Altuntas H, Ozpolat B.
    Cell Signal; 2021 Jul 04; 83():109979. PubMed ID: 33744419
    [Abstract] [Full Text] [Related]

  • 19. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P.
    Oncotarget; 2015 Oct 13; 6(31):32115-37. PubMed ID: 26378051
    [Abstract] [Full Text] [Related]

  • 20. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
    Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, Chang G, Li X, Li Q, Wang S, Wang W.
    PLoS One; 2014 Oct 13; 9(5):e96228. PubMed ID: 24788655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.